The transferrin receptor and the targeted delivery of therapeutic agents against cancer

Biochimica et Biophysica Acta - General Subjects

Volumn 1820, Issue 3, 2012, Pages 291-317

  Daniels, Tracy R ^a   Bernabeu, Ezequiel ^b,c   Rodríguez, José A ^a,d   Patel, Shabnum ^a   Kozman, Maggie ^a   Chiappetta, Diego A ^b,c   Holler, Eggehard ^e   Ljubimova, Julia Y ^e   Helguera, Gustavo ^b,c   Penichet, Manuel L ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer; Conjugate; Delivery; Immunotoxin; Nanoparticle; Transferrin receptor

Indexed keywords

7D3 ANTIBODY RICIN TOXIN CHAIN A CONJUGATE; ANTINEOPLASTIC AGENT; ARTEMISININ TRANSFERRIN CONJUGATE; BETA LACTOGLOBULIN B POLYETHYLENE GLYCOL TRANSFERRIN CONJUGATE; CD71 ANTIGEN; CHLORAMBUCIL TRANSFERRIN CONJUGATE; CRM 107 TRANSFERRIN CONJUGATE; DAUNORUBICIN TRANSFERRIN CONJUGATE; DEFEROXAMINE MESYLATE; DIPHTHERIA TOXIN TRANSFERRIN CONJUGATE; DOXORUBICIN TRANSFERRIN; GALLIUM NITRATE; GEMCITABINE TRANSFERRIN CONJUGATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR R17 217 FUSION PROTEIN; HB21 ANTIBODY PSEUDOMONAS EXOTOXIN CONJUGATE; LIPOSOME; MITOMYCIN C TRANSFERRIN CONJUGATE; MONENSIN; MONOCLONAL ANTIBODY; MPTC 63; NANOPARTICLE; PEGYLATED TUMOR NECROSIS FACTOR ALPHA TRANSFERRIN CONJUGATE; PLATINUM COMPLEX; POLYETHYLENIMINE SHORT HAIRPIN RNA TRANSFERRIN CONJUGATE; POLYETHYLENIMINE TRANSFERRIN TUMOR NECROSIS FACTOR ALPHA CONJUGATE; R17 217 ANTIBODY RICIN TOXIN CHAIN A CONJUGATE; RICIN A TRANSFERRIN CONJUGATE; SAPORIN TRANSFERRIN CONJUGATE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASCITES TUMOR; ASTROCYTOMA; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BRAIN CANCER; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; COLON CARCINOMA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TISSUE LEVEL; EXTRAVASATION; GLIOBLASTOMA; GLIOMA; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER METASTASIS; LUNG METASTASIS; LYMPHATIC SYSTEM TUMOR; MELANOMA; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; MOUTH CARCINOMA; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; NEOPLASM; NEPHROTOXICITY; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PERITONEUM TUMOR; PRIORITY JOURNAL; REVIEW; SARCOMA; SINGLE DRUG DOSE; VIRAL GENE DELIVERY SYSTEM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARRIER PROTEINS; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; HUMANS; IRON; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, TRANSFERRIN;

EID: 84857371220     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2011.07.016     Document Type: Review

References (230)

1. T.R. Daniels, T. Delgado, J.A. Rodriguez, G. Helguera, and M.L. Penichet The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer Clin. Immunol. 121 2006 144 158 (Pubitemid 44592578)
2. Y. Cheng, O. Zak, P. Aisen, S.C. Harrison, and T. Walz Structure of the human transferrin receptor-transferrin complex Cell 116 2004 565 576 (Pubitemid 38264433)
3. H. Fuchs, U. Lucken, R. Tauber, A. Engel, and R. Gessner Structural model of phospholipid-reconstituted human transferrin receptor derived by electron microscopy Structure 6 1998 1235 1243 (Pubitemid 28485956)
4. J.A. Lebron, M.J. Bennett, D.E. Vaughn, A.J. Chirino, P.M. Snow, G.A. Mintier, J.N. Feder, and P.J. Bjorkman Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor Cell 93 1998 111 123 (Pubitemid 28173557)
5. M. Hemadi, P.H. Kahn, G. Miquel, and J.M. El Hage Chahine Transferrin's mechanism of interaction with receptor 1 Biochemistry 43 2004 1736 1745 (Pubitemid 38200580)
6. A. Ciechanover, A.L. Schwartz, and H.F. Lodish Sorting and recycling of cell surface receptors and endocytosed ligands: the asialoglycoprotein and transferrin receptors J. Cell. Biochem. 23 1983 107 130 (Pubitemid 14138507)
7. D.C. Yang, F. Wang, R.L. Elliott, and J.F. Head Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer Anticancer Res. 21 2001 541 549 (Pubitemid 32267568)
8. R. Prior, G. Reifenberger, and W. Wechsler Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction Virchows Arch. A Pathol. Anat. Histopathol. 416 1990 491 496 (Pubitemid 20141928)
9. A. Das Gupta, and V.I. Shah Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin's lymphoma Hematol. Pathol. 4 1990 37 41 (Pubitemid 20137129)
10. J.A. Habeshaw, T.A. Lister, A.G. Stansfeld, and M.F. Greaves Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma Lancet 1 1983 498 501
11. K. Kondo, M. Noguchi, K. Mukai, Y. Matsuno, Y. Sato, Y. Shimosato, and Y. Monden Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis Chest 97 1990 1367 1371 (Pubitemid 20185681)
12. G.J. Seymour, M.D. Walsh, M.F. Lavin, G. Strutton, and R.A. Gardiner Transferrin receptor expression by human bladder transitional cell carcinomas Urol. Res. 15 1987 341 344
13. S. White, R. Taetle, P.A. Seligman, M. Rutherford, and I.S. Trowbridge Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects Cancer Res. 50 1990 6295 6301 (Pubitemid 20323691)
14. C. Callens, I.C. Moura, Y. Lepelletier, S. Coulon, A. Renand, M. Dussiot, D. Ghez, M. Benhamou, R.C. Monteiro, A. Bazarbachi, and O. Hermine Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody Leukemia 22 2008 42 48
15. P.P. Ng, J.S. Dela Cruz, D.N. Sorour, J.M. Stinebaugh, S.U. Shin, D.S. Shin, S.L. Morrison, and M.L. Penichet An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells Proc. Natl. Acad. Sci. U.S.A. 99 2002 10706 10711
16. P.P. Ng, G. Helguera, T.R. Daniels, S.Z. Lomas, J.A. Rodriguez, G. Schiller, B. Bonavida, S.L. Morrison, and M.L. Penichet Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor Blood 108 2006 2745 2754
17. X. Wang, L. Yang, Z.G. Chen, and D.M. Shin Application of nanotechnology in cancer therapy and imaging CA Cancer J. Clin. 58 2008 97 110 (Pubitemid 351521865)
18. B. Haley, and E. Frenkel Nanoparticles for drug delivery in cancer treatment Urol. Oncol. 26 2008 57 64
19. S.M. Moghimi, A.C. Hunter, and J.C. Murray Nanomedicine: current status and future prospects FASEB J. 19 2005 311 330 (Pubitemid 40316520)
20. P. Sapra, and T.M. Allen Ligand-targeted liposomal anticancer drugs Prog. Lipid Res. 42 2003 439 462 (Pubitemid 36700404)
21. D.W. Northfelt, F.J. Martin, P. Working, P.A. Volberding, J. Russell, M. Newman, M.A. Amantea, and L.D. Kaplan Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma J. Clin. Pharmacol. 36 1996 55 63 (Pubitemid 26058811)
22. M.C. Perry Continuous Intravenous Infusion Chemotherapy J.W. Pine, The Chemotherapy Source Book 4th Edition 2008 Lippincott Williams and Wilkins Philadelphia, PA 79 87 vol.
23. M. Singh, H. Atwal, and R. Micetich Transferrin directed delivery of adriamycin to human cells Anticancer Res. 18 1998 1423 1427 (Pubitemid 28342540)
24. A. Berczi, K. Barabas, J.A. Sizensky, and W.P. Faulk Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells Arch. Biochem. Biophys. 300 1993 356 363 (Pubitemid 23225757)
25. F. Kratz, U. Beyer, T. Roth, N. Tarasova, P. Collery, F. Lechenault, A. Cazabat, P. Schumacher, C. Unger, and U. Falken Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy J. Pharm. Sci. 87 1998 338 346 (Pubitemid 28204588)
26. K. Barabas, J.A. Sizensky, and W.P. Faulk Evidence in support of the plasma membrane as the target for transferrin-adriamycin conjugates in K562 cells Am. J. Reprod. Immunol. 25 1991 120 123
27. I.L. Sun, E.E. Sun, F.L. Crane, D.J. Morre, and W.P. Faulk Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates Biochim. Biophys. Acta 1105 1992 84 88
28. M. Fritzer, K. Barabas, V. Szuts, A. Berczi, T. Szekeres, W.P. Faulk, and H. Goldenberg Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells Int. J. Cancer 52 1992 619 623
29. T. Hatano, K. Ohkawa, and M. Matsuda Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro Tumour Biol. 14 1993 288 294 (Pubitemid 23357717)
30. B.T. Lai, J.P. Gao, and K.W. Lanks Mechanism of action and spectrum of cell lines sensitive to a doxorubicin-transferrin conjugate Cancer Chemother. Pharmacol. 41 1998 155 160 (Pubitemid 28096270)
31. K. Barabas, J.A. Sizensky, and W.P. Faulk Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA J. Biol. Chem. 267 1992 9437 9442
32. M. Fritzer, T. Szekeres, V. Szuts, H.N. Jarayam, and H. Goldenberg Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells Biochem. Pharmacol. 51 1996 489 493 (Pubitemid 26072568)
33. D. Lubgan, Z. Jozwiak, G.G. Grabenbauer, and L.V. Distel Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells Cell. Mol. Biol. Lett. 14 2009 113 127
34. C.R. Chitambar Gallium compounds as antineoplastic agents Curr. Opin. Oncol. 16 2004 547 552 (Pubitemid 39482973)
35. F. Wang, X. Jiang, D.C. Yang, R.L. Elliott, and J.F. Head Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells Anticancer Res. 20 2000 799 808 (Pubitemid 30240636)
36. R.L. Elliott, R. Stjernholm, and M.C. Elliott Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer Cancer Detect. Prev. 12 1988 469 480
37. J.F. Head, F. Wang, and R.L. Elliott Antineoplastic drugs that interfere with iron metabolism in cancer cells Adv. Enzyme Regul. 37 1997 147 169 (Pubitemid 27371560)
38. R.L. Elliott, and J.F. Head Complete resolution of malignant ascites in stage IV breast cancer by peritoneal drainage and innovative chemoimmunotherapy: a case report Cancer Biother. Radiopharm. 21 2006 138 145 (Pubitemid 43830435)
39. U. Beyer, T. Roth, P. Schumacher, G. Maier, A. Unold, A.W. Frahm, H.H. Fiebig, C. Unger, and F. Kratz Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil J. Med. Chem. 41 1998 2701 2708 (Pubitemid 28350337)
40. T. Tanaka, S. Shiramoto, M. Miyashita, Y. Fujishima, and Y. Kaneo Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME) Int. J. Pharm. 277 2004 39 61 (Pubitemid 38670420)
41. N. Bejaoui, M. Page, and C. Noel Cytotoxicity of transferrin-daunorubicin conjugates on small cell carcinoma of the lung (SCCL) cell line NCI-H69 Anticancer Res. 11 1991 2211 2213
42. G.L. Mayers, D. Raghavan, S. Hitt, and D. Glaves Transferrin-gemcitabine conjugate: application to chemotherapy Proceedings of the American Association for Cancer Research, vol. 89th, New Orleans, Louisiana, USA 1998 63
43. V. Raso, and M. Basala A highly cytotoxic human transferrin-ricin A chain conjugate used to select receptor-modified cells J. Biol. Chem. 259 1984 1143 1149 (Pubitemid 14193265)
44. R. Chignola, R. Foroni, A. Franceschi, M. Pasti, C. Candiani, C. Anselmi, G. Fracasso, G. Tridente, and M. Colombatti Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin Br. J. Cancer 72 1995 607 614
45. G. Bergamaschi, M. Cazzola, L. Dezza, E. Savino, L. Consonni, and D. Lappi Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6) Br. J. Haematol. 68 1988 379 384
46. R. Ippoliti, E. Lendaro, I. D'Agostino, M.L. Fiani, D. Guidarini, S. Vestri, P.A. Benedetti, and M. Brunori A chimeric saporin-transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity FASEB J. 9 1995 1220 1225
47. P.H. Gosselaar, A.J. van-Dijk, G.C. de-Gast, L. Polito, A. Bolognesi, W.C. Vooijs, A.F. Verheul, H.G. Krouwer, and J.J. Marx Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation Eur. J. Clin. Invest. 32 Suppl. 1 2002 61 69 (Pubitemid 41704990)
48. A. Cimini, S. Mei, E. Benedetti, G. Laurenti, I. Koutris, B. Cinque, M.G. Cifone, R. Galzio, G. Pitari, L.D. Leandro, F. Giansanti, A. Lombardi, M.S. Fabbrini, and R. Ippoliti Distinct cellular responses induced by saporin and a transferrin-saporin conjugate in two different human glioblastoma cell lines J. Cell. Physiol. 2011 Apr 18. doi: 10.1002/jcp.22805. [Epub ahead of print]
49. D.O. O'Keefe, and R.K. Draper Characterization of a transferrin- diphtheria toxin conjugate J. Biol. Chem. 260 1985 932 937 (Pubitemid 15125585)
50. D.J. Yoon, D.S. Chu, C.W. Ng, E.A. Pham, A.B. Mason, D.M. Hudson, V.C. Smith, R.T. MacGillivray, and D.T. Kamei Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins J. Control. Release 133 2009 178 184
51. D.J. Yoon, B.H. Kwan, F.C. Chao, T.P. Nicolaides, J.J. Phillips, G.Y. Lam, A.B. Mason, W.A. Weiss, and D.T. Kamei Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery Cancer Res. 70 2010 4520 4527
52. V.G. Johnson, C. Wrobel, D. Wilson, J. Zovickian, L. Greenfield, E.H. Oldfield, and R. Youle Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia J. Neurosurg. 70 1989 240 248 (Pubitemid 19051721)
53. L.A. Martell, A. Agrawal, D.A. Ross, and K.M. Muraszko Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors Cancer Res. 53 1993 1348 1353 (Pubitemid 23097115)
54. D.W. Laske, R.J. Youle, and E.H. Oldfield Tumor regression with regional distribution of the targeted toxin Tf-CRM107 in patients with malignant brain tumors Nat. Med. 3 1997 1362 1368 (Pubitemid 28011036)
55. M. Weaver, and D.W. Laske Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas J. Neurooncol. 65 2003 3 13 (Pubitemid 37441310)
56. H. Lai, T. Sasaki, and N.P. Singh Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds Expert Opin. Ther. Targets 9 2005 995 1007 (Pubitemid 41488836)
57. I. Nakase, H. Lai, N.P. Singh, and T. Sasaki Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation Int. J. Pharm. 354 2008 28 33 (Pubitemid 351400327)
58. I. Nakase, B. Gallis, T. Takatani-Nakase, S. Oh, E. Lacoste, N.P. Singh, D.R. Goodlett, S. Tanaka, S. Futaki, H. Lai, and T. Sasaki Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis Cancer Lett. 274 2009 290 298
59. H. Lai, I. Nakase, E. Lacoste, N.P. Singh, and T. Sasaki Artemisinin-transferrin conjugate retards growth of breast tumors in the rat Anticancer Res. 29 2009 3807 3810
60. Y. Jiang, G. Tang, M. Hong, S. Zhu, C. Fang, B. Shi, and Y. Pei Active tumor-targeted delivery of PEG-protein via transferrin-transferrin-receptor system J. Drug Target. 15 2007 672 683 (Pubitemid 350201320)
61. Y.Y. Jiang, C. Liu, M.H. Hong, S.J. Zhu, and Y.Y. Pei Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation Bioconjug. Chem. 18 2007 41 49 (Pubitemid 46145993)
62. S.M. Rybak, D.L. Newton, S.M. Mikulski, A. Viera, and R. Youle Cytotoxic onconase and ribonuclease A chimeras: comparison and in vitro characterization Drug Deliv. 1 1993 3 10
63. M. Suzuki, S.K. Saxena, E. Boix, R.J. Prill, V.M. Vasandani, J.E. Ladner, C. Sung, and R.J. Youle Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction Nat. Biotechnol. 17 1999 265 270 (Pubitemid 29122635)
64. C.M. Ward, M.L. Read, and L.W. Seymour Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy Blood 97 2001 2221 2229 (Pubitemid 32291466)
65. M.X. Tang, and F.C. Szoka The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes Gene Ther. 4 1997 823 832 (Pubitemid 27380165)
66. E. Wagner, M. Zenke, M. Cotten, H. Beug, and M.L. Birnstiel Transferrin-polycation conjugates as carriers for DNA uptake into cells Proc. Natl. Acad. Sci. U.S.A. 87 1990 3410 3414
67. K. Zatloukal, E. Wagner, M. Cotten, S. Phillips, C. Plank, P. Steinlein, D.T. Curiel, and M.L. Birnstiel Transferrinfection: a highly efficient way to express gene constructs in eukaryotic cells Ann. N. Y. Acad. Sci. 660 1992 136 153 (Pubitemid 23054724)
68. M. Cotten, F. Langle-Rouault, H. Kirlappos, E. Wagner, K. Mechtler, M. Zenke, H. Beug, and M.L. Birnstiel Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels Proc. Natl. Acad. Sci. U.S.A. 87 1990 4033 4037
69. E. Wagner, M. Cotten, K. Mechtler, H. Kirlappos, and M.L. Birnstiel DNA-binding transferrin conjugates as functional gene-delivery agents: synthesis by linkage of polylysine or ethidium homodimer to the transferrin carbohydrate moiety Bioconjug. Chem. 2 1991 226 231
70. D.J. Taxman, E.S. Lee, and D.M. Wojchowski Receptor-targeted transfection using stable maleimido-transferrin/thio-poly-L-lysine conjugates Anal. Biochem. 213 1993 97 103 (Pubitemid 23250622)
71. E. Wagner, C. Plank, K. Zatloukal, M. Cotten, and M.L. Birnstiel Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle Proc. Natl. Acad. Sci. U.S.A. 89 1992 7934 7938
72. C. Plank, B. Oberhauser, K. Mechtler, C. Koch, and E. Wagner The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems J. Biol. Chem. 269 1994 12918 12924 (Pubitemid 24202092)
73. L. Wightman, E. Patzelt, E. Wagner, and R. Kircheis Development of transferrin-polycation/DNA based vectors for gene delivery to melanoma cells J. Drug Target. 7 1999 293 303 (Pubitemid 30098689)
74. M. Ogris, S. Brunner, S. Schuller, R. Kircheis, and E. Wagner PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery Gene Ther. 6 1999 595 605 (Pubitemid 29192668)
75. R. Kircheis, S. Schuller, S. Brunner, M. Ogris, K.H. Heider, W. Zauner, and E. Wagner Polycation-based DNA complexes for tumor-targeted gene delivery in vivo J. Gene Med. 1 1999 111 120 (Pubitemid 129631068)
76. D.E. Hallahan, E.E. Vokes, S.J. Rubin, S. O'Brien, B. Samuels, S. Vijaykumar, D.W. Kufe, R. Phillips, and R.R. Weichselbaum Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy Cancer J. Sci. Am. 1 1995 204 209
77. R. Kircheis, E. Ostermann, M.F. Wolschek, C. Lichtenberger, C. Magin-Lachmann, L. Wightman, M. Kursa, and E. Wagner Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity Cancer Gene Ther. 9 2002 673 680 (Pubitemid 34847575)
78. M. Kursa, G.F. Walker, V. Roessler, M. Ogris, W. Roedl, R. Kircheis, and E. Wagner Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer Bioconjug. Chem. 14 2003 222 231 (Pubitemid 36169036)
79. Y. Liu, J. Tao, Y. Li, J. Yang, Y. Yu, M. Wang, X. Xu, C. Huang, W. Huang, J. Dong, L. Li, J. Liu, G. Shen, and Y. Tu Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth Mol. Ther. 17 2009 269 277
80. M.Y. Koh, T.R. Spivak-Kroizman, and G. Powis HIF-1alpha and cancer therapy Recent Results Cancer Res. 180 2010 15 34
81. X. Zeng, Y.X. Sun, W. Qu, X.Z. Zhang, and R.X. Zhuo Biotinylated transferrin/avidin/biotinylated disulfide containing PEI bioconjugates mediated p53 gene delivery system for tumor targeted transfection Biomaterials 31 2010 4771 4780
82. Y. Sato, N. Yamauchi, M. Takahashi, K. Sasaki, J. Fukaura, H. Neda, S. Fujii, M. Hirayama, Y. Itoh, Y. Koshita, K. Kogawa, J. Kato, S. Sakamaki, and Y. Niitsu In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate FASEB J. 14 2000 2108 2118
83. M.J. Bjorn, and G. Groetsema Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors Cancer Res. 47 1987 6639 6645 (Pubitemid 18019669)
84. J. Lesley, D.L. Domingo, R. Schulte, and I.S. Trowbridge Effect of an anti-murine transferrin receptor-ricin A conjugate on bone marrow stem and progenitor cells treated in vitro Exp. Cell Res. 150 1984 400 407 (Pubitemid 14192480)
85. T. Dreier, H.N. Lode, R. Xiang, C.S. Dolman, R.A. Reisfeld, and A.S. Kang Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities Bioconjug. Chem. 9 1998 482 489 (Pubitemid 28338763)
86. Y. Shi, C.H. Liu, A.I. Roberts, J. Das, G. Xu, G. Ren, Y. Zhang, L. Zhang, Z.R. Yuan, H.S. Tan, G. Das, and S. Devadas Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know Cell Res. 16 2006 126 133 (Pubitemid 43247967)
87. K. Inaba, M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R.M. Steinman Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor J. Exp. Med. 176 1992 1693 1702
88. B.F. Haynes, M. Hemler, T. Cotner, D.L. Mann, G.S. Eisenbarth, J.L. Strominger, and A.S. Fauci Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation J. Immunol. 127 1981 347 351 (Pubitemid 11075506)
89. R. Pirker, D.J. FitzGerald, T.C. Hamilton, R.F. Ozols, M.C. Willingham, and I. Pastan Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines Cancer Res. 45 1985 751 757 (Pubitemid 15161076)
90. R. Pirker, D.J. FitzGerald, M.C. Willingham, and I. Pastan Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines Cancer Res. 48 1988 3919 3923
91. H. Shinohara, D. Fan, S. Ozawa, S. Yano, M. Van Arsdell, J.L. Viner, R. Beers, I. Pastan, and I.J. Fidler Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin Int. J. Oncol. 17 2000 643 651
92. J.K. Batra, D.J. Fitzgerald, V.K. Chaudhary, and I. Pastan Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv) Mol. Cell. Biol. 11 1991 2200 2205 (Pubitemid 21895592)
93. R. Traini, G. Ben-Josef, D.V. Pastrana, E. Moskatel, A.K. Sharma, A. Antignani, and D.J. Fitzgerald ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol Mol. Cancer Ther. 9 2010 2007 2015
94. J.K. Batra, Y. Jinno, V.K. Chaudhary, T. Kondo, M.C. Willingham, D.J. FitzGerald, and I. Pastan Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin Proc. Natl. Acad. Sci. U.S.A. 86 1989 8545 8549 (Pubitemid 19286092)
95. C.F. Scott Jr. , V.S. Goldmacher, J.M. Lambert, J.V. Jackson, and G.D. McIntyre An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors J. Natl. Cancer Inst. 79 1987 1163 1172 (Pubitemid 17165290)
96. S. Ramakrishnan, and L.L. Houston Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: potentiation by chloroquine Science 223 1984 58 61 (Pubitemid 14209909)
97. S. Ramakrishnan, J.J. Enghlid, H.L. Bryant Jr. , and F.J. Xu Characterization of a translation inhibitory protein from Luffa aegyptiaca Biochem. Biophys. Res. Commun. 160 1989 509 516 (Pubitemid 19140574)
98. G.R. Braslawsky, K. Kadow, J. Knipe, K. McGoff, M. Edson, T. Kaneko, and R.S. Greenfield Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity Cancer Immunol. Immunother. 33 1991 367 374
99. D. Rathore, and J.K. Batra Construction, expression and characterization of chimaeric toxins containing the ribonucleolytic toxin restrictocin: intracellular mechanism of action Biochem. J. 324 Pt 3 1997 815 822 (Pubitemid 27285539)
100. A. Goyal, and J.K. Batra Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins Biochem. J. 345 Pt 2 2000 247 254 (Pubitemid 30077164)
101. D. Rathore, and J.K. Batra Generation of active immunotoxins containing recombinant restrictocin Biochem. Biophys. Res. Commun. 222 1996 58 63 (Pubitemid 26160053)
102. D. Rathore, S.K. Nayak, and J.K. Batra Overproduction of fungal ribotoxin alpha-sarcin in Escherichia coli: generation of an active immunotoxin Gene 190 1997 31 35 (Pubitemid 27214267)
103. J.W. Pearson, E. Hedrick, W.E. Fogler, R.L. Bull, D.K. Ferris, C.W. Riggs, R.H. Wiltrout, G. Sivam, A.C. Morgan, and E. Groves Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon Cancer Res. 50 1990 6379 6388 (Pubitemid 20323704)
104. D.W. Laske, O. Ilercil, A. Akbasak, R.J. Youle, and E.H. Oldfield Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice J. Neurosurg. 80 1994 520 526 (Pubitemid 24073015)
105. D.W. Laske, K.M. Muraszko, E.H. Oldfield, H.L. DeVroom, C. Sung, R.L. Dedrick, T.R. Simon, J. Colandrea, C. Copeland, D. Katz, L. Greenfield, E.S. Groves, L.L. Houston, and R.J. Youle Intraventricular immunotoxin therapy for leptomeningeal neoplasia Neurosurgery 41 1997 1039 1049 discussion 1049-1051
106. V. Ghetie, and E. Vitetta Immunotoxins in the therapy of cancer: from bench to clinic Pharmacol. Ther. 63 1994 209 234 (Pubitemid 24315749)
107. I.S. Trowbridge, and D.L. Domingo Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells Nature 294 1981 171 173 (Pubitemid 12217978)
108. M. Cazzola, G. Bergamaschi, L. Dezza, R. D'Uva, L. Ponchio, V. Rosti, and E. Ascari Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors Cancer Res. 51 1991 536 541
109. S.M. Rybak, S.K. Saxena, E.J. Ackerman, and R.J. Youle Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins J. Biol. Chem. 266 1991 21202 21207 (Pubitemid 21908595)
110. L.D. Recht, T.W. Griffin, V. Raso, and A.R. Salimi Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro Cancer Res. 50 1990 6696 6700 (Pubitemid 20348802)
111. T. Griffin, and V. Raso Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins Cancer Res. 51 1991 4316 4322
112. T.W. Griffin, M. Stocl, J. Collins, J. Fernandes, and V.E. Maher Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies J. Immunother. (1991) 11 1992 12 18
113. J. Li, X. Weng, Z. Liang, M. Zhong, X. Chen, S. Lu, W. Sun, Y. Song, X. Wu, and G. Shen Viral specific cytotoxic T cells inhibit the growth of TfR-expressing tumor cells with antibody targeted viral peptide/HLA-A2 complex Cell. Immunol. 263 2010 154 160
114. D.L. Newton, D. Pollock, P. DiTullio, Y. Echelard, M. Harvey, B. Wilburn, J. Williams, H.R. Hoogenboom, J.C. Raus, H.M. Meade, and S.M. Rybak Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice J. Immunol. Methods 231 1999 159 167 (Pubitemid 30394731)
115. S.M. Rybak, H.R. Hoogenboom, H.M. Meade, J.C. Raus, D. Schwartz, and R.J. Youle Humanization of immunotoxins Proc. Natl. Acad. Sci. U.S.A. 89 1992 3165 3169
116. D.L. Newton, P.J. Nicholls, S.M. Rybak, and R.J. Youle Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv J. Biol. Chem. 269 1994 26739 26745 (Pubitemid 24332866)
117. M. Zewe, S.M. Rybak, S. Dubel, J.F. Coy, M. Welschof, D.L. Newton, and M. Little Cloning and cytotoxicity of a human pancreatic RNase immunofusion Immunotechnology 3 1997 127 136 (Pubitemid 27356791)
118. D.L. Newton, Y. Xue, K.A. Olson, J.W. Fett, and S.M. Rybak Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains Biochemistry 35 1996 545 553 (Pubitemid 26032706)
119. T. Asai, R. Trinh, P.P. Ng, M.L. Penichet, L.A. Wims, and S.L. Morrison A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery Biomol. Eng. 21 2005 145 155 (Pubitemid 40313413)
120. E. Ortiz-Sanchez, T.R. Daniels, G. Helguera, O. Martinez-Maza, B. Bonavida, and M.L. Penichet Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species Leukemia 23 2009 59 70
121. T.R. Daniels, E. Ortiz-Sanchez, R. Luria-Perez, R. Quintero, G. Helguera, B. Bonavida, O. Martinez-Maza, and M.L. Penichet An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies J. Immunother. 34 2011 500 508
122. T.R. Daniels, P.P. Ng, T. Delgado, M.R. Lynch, G. Schiller, G. Helguera, and M.L. Penichet Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells Mol. Cancer Ther. 6 2007 2995 3008 (Pubitemid 350206778)
123. S. Oh, B.J. Kim, N.P. Singh, H. Lai, and T. Sasaki Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide Cancer Lett. 274 2009 33 39
124. A.N. Lukyanov, and V.P. Torchilin Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs Adv. Drug Deliv. Rev. 56 2004 1273 1289 (Pubitemid 38510474)
125. D.A. Chiappetta, and A. Sosnik Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs Eur. J. Pharm. Biopharm. 66 2007 303 317 (Pubitemid 46756232)
126. R. Savic, L. Luo, A. Eisenberg, and D. Maysinger Micellar nanocontainers distribute to defined cytoplasmic organelles Science 300 2003 615 618 (Pubitemid 36520581)
127. D. Khan The use of nanocarriers for drug delivery in cancer therapy J. Cancer Sci. Ther. 2 2010 058 062
128. M. Jones, and J. Leroux Polymeric micelles - a new generation of colloidal drug carriers Eur. J. Pharm. Biopharm. 48 1999 101 111 (Pubitemid 29401986)
129. E. Blanco, C.W. Kessinger, B.D. Sumer, and J. Gao Multifunctional micellar nanomedicine for cancer therapy Exp. Biol. Med. (Maywood) 234 2009 123 131
130. K.M. Huh, H.S. Min, S.C. Lee, H.J. Lee, S. Kim, and K. Park A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel J. Control. Release 126 2008 122 129
131. M. Licciardi, G. Giammona, J. Du, S.P. Armes, Y. Tang, and A.L. Lewis New folate-functionalized biocompatible block copolymer micelles as potential anti-cancer drug delivery systems Polymer 47 2006 2946 2955
132. F. Danhier, N. Magotteaux, B. Ucakar, N. Lecouturier, M. Brewster, and V. Preat Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel Eur. J. Pharm. Biopharm. 73 2009 230 238
133. M. Yokoyama, T. Okano, Y. Sakurai, S. Fukushima, K. Okamoto, and K. Kataoka Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system J. Drug Target. 7 1999 171 186 (Pubitemid 30028961)
134. G. Gaucher, M.H. Dufresne, V.P. Sant, N. Kang, D. Maysinger, and J.C. Leroux Block copolymer micelles: preparation, characterization and application in drug delivery J. Control. Release 109 2005 169 188 (Pubitemid 41742123)
135. S. Vinogradov, E. Batrakova, S. Li, and A. Kabanov Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells Bioconjug. Chem. 10 1999 851 860 (Pubitemid 29456374)
136. W.H. Ren, J. Chang, C.H. Yan, X.M. Qian, L.X. Long, B. He, X.B. Yuan, C.S. Kang, D. Betbeder, J. Sheng, and P.Y. Pu Development of transferrin functionalized poly(ethylene glycol)/poly(lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma J. Mater. Sci. Mater. Med. 21 2010 2673 2681
137. A. Agarwal, S. Saraf, A. Asthana, U. Gupta, V. Gajbhiye, and N.K. Jain Ligand based dendritic systems for tumor targeting Int. J. Pharm. 350 2008 3 13
138. F. Zeng, and S.C. Zimmerman Dendrimers in supramolecular chemistry: from molecular recognition to self-assembly Chem. Rev. 97 1997 1681 1712 (Pubitemid 127659610)
139. U. Boas, and P.M. Heegaard Dendrimers in drug research Chem. Soc. Rev. 33 2004 43 63 (Pubitemid 38376610)
140. F. Aulenta, W. Hayes, and S. Rannard Dendrimers: a new class of nanoscopic containers and delivery devices Eur. Polym. J. 39 2003 1741
141. D.A. Tomalia The dendritic state Mater. Today 2005 34 46 (Pubitemid 40244963)
142. M. Liu, and J.M. Frechet Designing dendrimers for drug delivery Pharm. Sci. Technol. Today 2 1999 393 401 (Pubitemid 29452933)
143. D. Bhadra, S. Bhadra, S. Jain, and N.K. Jain A PEGylated dendritic nanoparticulate carrier of fluorouracil Int. J. Pharm. 257 2003 111 124 (Pubitemid 36507038)
144. C.C. Lee, E.R. Gillies, M.E. Fox, S.J. Guillaudeu, J.M. Frechet, E.E. Dy, and F.C. Szoka A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas Proc. Natl. Acad. Sci. U.S.A. 103 2006 16649 16654 (Pubitemid 44737307)
145. L. Vincent, J. Varet, J.Y. Pille, H. Bompais, P. Opolon, A. Maksimenko, C. Malvy, M. Mirshahi, H. Lu, J.P. Vannier, C. Soria, and H. Li Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: in vitro and in vivo studies Int. J. Cancer 105 2003 419 429 (Pubitemid 36570058)
146. B.K. Nanjwade, H.M. Bechra, G.K. Derkar, F.V. Manvi, and V.K. Nanjwade Dendrimers: emerging polymers for drug-delivery systems Eur. J. Pharm. Sci. 38 2009 185 196
147. U. Gupta, S.K. Dwivedi, H.K. Bid, R. Konwar, and N.K. Jain Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells Int. J. Pharm. 393 2010 185 196
148. S. Koppu, Y.J. Oh, R. Edrada-Ebel, D.R. Blatchford, L. Tetley, R.J. Tate, and C. Dufes Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA J. Control. Release 143 2010 215 221
149. L. Han, R. Huang, S. Liu, S. Huang, and C. Jiang Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors Mol. Pharm. 7 2010 2156 2165
150. L. Han, R. Huang, J. Li, S. Liu, S. Huang, and C. Jiang Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer Biomaterials 32 2011 1242 1252
151. H. He, Y. Li, X.R. Jia, J. Du, X. Ying, W.L. Lu, J.N. Lou, and Y. Wei PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors Biomaterials 32 2011 478 487
152. C. Pinto Reis, R.J. Neufeld, A.J. Ribeiro, and F. Veiga Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles Nanomedicine 2 2006 8 21
153. R.A. Jain The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices Biomaterials 21 2000 2475 2490
154. K.S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, and W.E. Rudzinski Biodegradable polymeric nanoparticles as drug delivery devices J. Control. Release 70 2001 1 20 (Pubitemid 32144788)
155. I. Brigger, C. Dubernet, and P. Couvreur Nanoparticles in cancer therapy and diagnosis Adv. Drug Deliv. Rev. 54 2002 631 651 (Pubitemid 35247520)
156. K. Letchford, and H. Burt A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes Eur. J. Pharm. Biopharm. 65 2007 259 269 (Pubitemid 46321600)
157. J. Wang, S. Tian, R.A. Petros, M.E. Napier, and J.M. Desimone The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies J. Am. Chem. Soc. 132 2010 11306 11313
158. Z. Liu, Y. Jiao, Y. Wang, C. Zhou, and Z. Zhang Polysaccharides-based nanoparticles as drug delivery systems Adv. Drug Deliv. Rev. 60 2008 1650 1662
159. K. Nagpal, S.K. Singh, and D.N. Mishra Chitosan nanoparticles: a promising system in novel drug delivery Chem. Pharm. Bull. (Tokyo) 58 2010 1423 1430
160. B.S. Lee, M. Fujita, N.M. Khazenzon, K.A. Wawrowsky, S. Wachsmann-Hogiu, D.L. Farkas, K.L. Black, J.Y. Ljubimova, and E. Holler Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery Bioconjug. Chem. 17 2006 317 326
161. Y. Zheng, B. Yu, W. Weecharangsan, L. Piao, M. Darby, Y. Mao, R. Koynova, X. Yang, H. Li, S. Xu, L.J. Lee, Y. Sugimoto, R.W. Brueggemeier, and R.J. Lee Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells Int. J. Pharm. 390 2011 234 241
162. S.K. Sahoo, W. Ma, and V. Labhasetwar Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer Int. J. Cancer 112 2004 335 340 (Pubitemid 39244375)
163. S.K. Sahoo, and V. Labhasetwar Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention Mol. Pharm. 2 2005 373 383 (Pubitemid 41503678)
164. N. Shah, K. Chaudhari, P. Dantuluri, R.S. Murthy, and S. Das Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model J. Drug Target. 17 2009 533 542
165. M. Pulkkinen, J. Pikkarainen, T. Wirth, T. Tarvainen, V. Haapa-aho, H. Korhonen, J. Seppala, and K. Jarvinen Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: formulation development and in vitro anticancer activity Eur. J. Pharm. Biopharm. 70 2008 66 74
166. Z. Xu, W. Gu, J. Huang, H. Sui, Z. Zhou, Y. Yang, Z. Yan, and Y. Li In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery Int. J. Pharm. 288 2005 361 368 (Pubitemid 40038589)
167. M. Hong, S. Zhu, Y. Jiang, G. Tang, C. Sun, C. Fang, B. Shi, and Y. Pei Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles J. Control. Release 141 2010 22 29
168. C.W. Gan, and S.S. Feng Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier Biomaterials 31 2010 7748 7757
169. Y. Li, M. Ogris, E. Wagner, J. Pelisek, and M. Ruffer Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation Int. J. Pharm. 259 2003 93 101 (Pubitemid 36638557)
170. Y. Aktas, M. Yemisci, K. Andrieux, R.N. Gursoy, M.J. Alonso, E. Fernandez-Megia, R. Novoa-Carballal, E. Quinoa, R. Riguera, M.F. Sargon, H.H. Celik, A.S. Demir, A.A. Hincal, T. Dalkara, Y. Capan, and P. Couvreur Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 Bioconjug. Chem. 16 2005 1503 1511 (Pubitemid 41681517)
171. B. Kateb, K. Chiu, K.L. Black, V. Yamamoto, B. Khalsa, J.Y. Ljubimova, H. Ding, R. Patil, J.A. Portilla-Arias, M. Modo, D.F. Moore, K. Farahani, M.S. Okun, N. Prakash, J. Neman, D. Ahdoot, W. Grundfest, S. Nikzad, and J.D. Heiss Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage 54 Suppl. 1 2011 S106 S124
172. D.R. Groothuis The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery Neuro Oncol. 2 2000 45 59
173. J.Y. Ljubimova, M. Fujita, N.M. Khazenzon, B.S. Lee, S. Wachsmann-Hogiu, D.L. Farkas, K.L. Black, and E. Holler Nanoconjugate based on polymalic acid for tumor targeting Chem. Biol. Interact. 171 2008 195 203
174. R. Patil, J. Portilla-Arias, H. Ding, S. Inoue, B. Konda, J. Hu, K.A. Wawrowsky, P.K. Shin, K.L. Black, E. Holler, and J.Y. Ljubimova Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(beta-L-malic acid) Pharm. Res. 27 2010 2317 2329
175. M. Fujita, N.M. Khazenzon, A.V. Ljubimov, B.S. Lee, I. Virtanen, E. Holler, K.L. Black, and J.Y. Ljubimova Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis Angiogenesis 9 2006 183 191
176. M. Fujita, B.S. Lee, N.M. Khazenzon, M.L. Penichet, K.A. Wawrowsky, R. Patil, H. Ding, E. Holler, K.L. Black, and J.Y. Ljubimova Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid) J. Control. Release 122 2007 356 363 (Pubitemid 47411593)
177. H. Ding, S. Inoue, A.V. Ljubimov, R. Patil, J. Portilla-Arias, J. Hu, B. Konda, K.A. Wawrowsky, M. Fujita, N. Karabalin, T. Sasaki, K.L. Black, E. Holler, and J.Y. Ljubimova Inhibition of brain tumor growth by intravenous poly (beta-L-malic acid) nanobioconjugate with pH-dependent drug release Proc. Natl. Acad. Sci. U.S.A. 107 2010 18143 18148
178. S. Inoue, H. Ding, J. Portilla-Arias, J. Hu, B. Konda, M. Fujita, A. Espinoza, S. Suhane, M. Riley, M. Gates, R. Patil, M.L. Penichet, A.V. Ljubimov, K.L. Black, E. Holler, and J.Y. Ljubimova Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity Cancer Res. 71 2011 1454 1464
179. Y. Malam, M. Loizidou, and A.M. Seifalian Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer Trends Pharmacol. Sci. 30 2009 592 599
180. Z. Drulis-Kawa, and A. Dorotkiewicz-Jach Liposomes as delivery systems for antibiotics Int. J. Pharm. 387 2010 187 198
181. R. Misra, S. Acharya, and S.K. Sahoo Cancer nanotechnology: application of nanotechnology in cancer therapy Drug Discov. Today 15 2010 842 850
182. O. Ishida, K. Maruyama, H. Tanahashi, M. Iwatsuru, K. Sasaki, M. Eriguchi, and H. Yanagie Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo Pharm. Res. 18 2001 1042 1048 (Pubitemid 32799953)
183. T. Kobayashi, T. Ishida, Y. Okada, S. Ise, H. Harashima, and H. Kiwada Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells Int. J. Pharm. 329 2007 94 102 (Pubitemid 44937528)
184. D.A. Eavarone, X. Yu, and R.V. Bellamkonda Targeted drug delivery to C6 glioma by transferrin-coupled liposomes J. Biomed. Mater. Res. 51 2000 10 14 (Pubitemid 30331976)
185. C. Fonseca, J.N. Moreira, C.J. Ciudad, M.C. Pedroso de Lima, and S. Simoes Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells Eur. J. Pharm. Biopharm. 59 2005 359 366 (Pubitemid 40127593)
186. X. Li, L. Ding, Y. Xu, Y. Wang, and Q. Ping Targeted delivery of doxorubicin using stealth liposomes modified with transferrin Int. J. Pharm. 373 2009 116 123
187. H. Iinuma, K. Maruyama, K. Okinaga, K. Sasaki, T. Sekine, O. Ishida, N. Ogiwara, K. Johkura, and Y. Yonemura Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer Int. J. Cancer 99 2002 130 137 (Pubitemid 34273210)
188. S. Xu, Y. Liu, H.C. Tai, J. Zhu, H. Ding, and R.J. Lee Synthesis of transferrin (Tf) conjugated liposomes via Staudinger ligation Int. J. Pharm. 404 2011 205 210
189. S. Anabousi, U. Bakowsky, M. Schneider, H. Huwer, C.M. Lehr, and C. Ehrhardt In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer Eur. J. Pharm. Sci. 29 2006 367 374 (Pubitemid 44709858)
190. L. Xu, P. Frederik, K.F. Pirollo, W.H. Tang, A. Rait, L.M. Xiang, W. Huang, I. Cruz, Y. Yin, and E.H. Chang Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery Hum. Gene Ther. 13 2002 469 481 (Pubitemid 34251511)
191. S.J. Chiu, S. Liu, D. Perrotti, G. Marcucci, and R.J. Lee Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes J. Control. Release 112 2006 199 207
192. X. Zhang, C.G. Koh, B. Yu, S. Liu, L. Piao, G. Marcucci, R.J. Lee, and L.J. Lee Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model Pharm. Res. 26 2009 1516 1524
193. J. Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, and R.J. Lee Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil J. Pharm. Pharm. Sci. 10 2007 350 357 (Pubitemid 350065179)
194. M.L. Krieger, N. Eckstein, V. Schneider, M. Koch, H.D. Royer, U. Jaehde, and G. Bendas Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro Int. J. Pharm. 389 2010 10 17
195. J. Huwyler, J. Yang, and W.M. Pardridge Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat J. Pharmacol. Exp. Ther. 282 1997 1541 1546 (Pubitemid 27408339)
196. S. Suzuki, K. Inoue, A. Hongoh, Y. Hashimoto, and Y. Yamazoe Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor Br. J. Cancer 76 1997 83 89 (Pubitemid 27250080)
197. A.S. Derycke, A. Kamuhabwa, A. Gijsens, T. Roskams, D. De Vos, A. Kasran, J. Huwyler, L. Missiaen, and P.A. de Witte Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells J. Natl. Cancer Inst. 96 2004 1620 1630 (Pubitemid 39534886)
198. N. Penacho, A. Filipe, S. Simoes, and M.C. Pedroso de Lima Transferrin-associated lipoplexes as gene delivery systems: relevance of mode of preparation and biophysical properties J. Membr. Biol. 221 2008 141 152
199. L. Xu, K.F. Pirollo, and E.H. Chang Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy J. Control. Release 74 2001 115 128 (Pubitemid 32727614)
200. L. Xu, K.F. Pirollo, W.H. Tang, A. Rait, and E.H. Chang Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts Hum. Gene Ther. 10 1999 2941 2952
201. L. Xu, K.F. Pirollo, and E.H. Chang Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro Hum. Gene Ther. 8 1997 467 475 (Pubitemid 27140549)
202. L. Xu, W.H. Tang, C.C. Huang, W. Alexander, L.M. Xiang, K.F. Pirollo, A. Rait, and E.H. Chang Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv Mol. Med. 7 2001 723 734 (Pubitemid 33070986)
203. L. Xu, C.C. Huang, W. Huang, W.H. Tang, A. Rait, Y.Z. Yin, I. Cruz, L.M. Xiang, K.F. Pirollo, and E.H. Chang Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes Mol. Cancer Ther. 1 2002 337 346
204. W. Yu, K.F. Pirollo, A. Rait, B. Yu, L.M. Xiang, W.Q. Huang, Q. Zhou, G. Ertem, and E.H. Chang A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene Gene Ther. 11 2004 1434 1440 (Pubitemid 39359434)
205. L.S. Mendonca, F. Firmino, J.N. Moreira, M.C. Pedroso de Lima, and S. Simoes Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment Bioconjug. Chem. 21 2010 157 168
206. T. Loftsson, and D. Duchene Cyclodextrins and their pharmaceutical applications Int. J. Pharm. 329 2007 1 11 (Pubitemid 44937538)
207. G. Wenz, B.H. Han, and A. Muller Cyclodextrin rotaxanes and polyrotaxanes Chem. Rev. 106 2006 782 817
208. M.E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol. Pharm. 6 2009 659 668
209. D.W. Bartlett, and M.E. Davis Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles Bioconjug. Chem. 18 2007 456 468 (Pubitemid 46493517)
210. N.C. Bellocq, S.H. Pun, G.S. Jensen, and M.E. Davis Transferrin- containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery Bioconjug. Chem. 14 2003 1122 1132 (Pubitemid 37449039)
211. S.H. Pun, F. Tack, N.C. Bellocq, J. Cheng, B.H. Grubbs, G.S. Jensen, M.E. Davis, M. Brewster, M. Janicot, B. Janssens, W. Floren, and A. Bakker Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles Cancer Biol. Ther. 3 2004 641 650 (Pubitemid 41351103)
212. S. Hu-Lieskovan, J.D. Heidel, D.W. Bartlett, M.E. Davis, and T.J. Triche Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma Cancer Res. 65 2005 8984 8992 (Pubitemid 41377390)
213. J.D. Heidel, Z. Yu, J.Y. Liu, S.M. Rele, Y. Liang, R.K. Zeidan, D.J. Kornbrust, and M.E. Davis Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA Proc. Natl. Acad. Sci. U.S.A. 104 2007 5715 5721 (Pubitemid 47175600)
214. M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen, J.D. Heidel, and A. Ribas Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
215. R. Waehler, S.J. Russell, and D.T. Curiel Engineering targeted viral vectors for gene therapy Nat. Rev. Genet. 8 2007 573 587 (Pubitemid 47077278)
216. E. Wagner, K. Zatloukal, M. Cotten, H. Kirlappos, K. Mechtler, D.T. Curiel, and M.L. Birnstiel Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes Proc. Natl. Acad. Sci. U.S.A. 89 1992 6099 6103
217. R. Kircheis, Z. Kupcu, G. Wallner, V. Rossler, T. Schweighoffer, and E. Wagner Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice Cancer Gene Ther. 7 2000 870 878 (Pubitemid 30437287)
218. S. Schreiber, E. Kampgen, E. Wagner, D. Pirkhammer, J. Trcka, H. Korschan, A. Lindemann, R. Dorffner, H. Kittler, F. Kasteliz, Z. Kupcu, A. Sinski, K. Zatloukal, M. Buschle, W. Schmidt, M. Birnstiel, R.E. Kempe, T. Voigt, H.A. Weber, H. Pehamberger, R. Mertelsmann, E.B. Brocker, K. Wolff, and G. Stingl Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study Hum. Gene Ther. 10 1999 983 993 (Pubitemid 29195428)
219. P. Schwarzenberger, J.D. Hunt, E. Robert, C. Theodossiou, and J.K. Kolls Receptor-targeted recombinant adenovirus conglomerates: a novel molecular conjugate vector with improved expression characteristics J. Virol. 71 1997 8563 8571 (Pubitemid 27446438)
220. P. Schwarzenberger, W. Huang, P. Oliver, T. Osidipe, C. Theodossiou, and J.K. Kolls Poly-L-lysine-based molecular conjugate vectors: a high efficiency gene transfer system for human progenitor and leukemia cells Am. J. Med. Sci. 321 2001 129 136 (Pubitemid 32128791)
221. F. Kreppel, J. Gackowski, E. Schmidt, and S. Kochanek Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors Mol. Ther. 12 2005 107 117 (Pubitemid 40862362)
222. M.U. Kaikkonen, H.P. Lesch, J. Pikkarainen, J.K. Raty, T. Vuorio, T. Huhtala, M. Taavitsainen, T. Laitinen, P. Tuunanen, O. Grohn, A. Narvanen, K.J. Airenne, and S. Yla-Herttuala (Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery Gene Ther. 16 2009 894 904
223. N. Pariente, K. Morizono, M.S. Virk, F.A. Petrigliano, R.E. Reiter, J.R. Lieberman, and I.S. Chen A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration Mol. Ther. 15 2007 1973 1981 (Pubitemid 350011737)
224. K. Morizono, Y. Xie, G. Helguera, T.R. Daniels, T.F. Lane, M.L. Penichet, and I.S. Chen A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide J. Gene Med. 11 2009 655 663
225. T. Shimbo, M. Kawachi, K. Saga, H. Fujita, T. Yamazaki, K. Tamai, and Y. Kaneda Development of a transferrin receptor-targeting HVJ-E vector Biochem. Biophys. Res. Commun. 364 2007 423 428 (Pubitemid 350026486)
226. M. Wu, T. Sherwin, W.L. Brown, and P.G. Stockley Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids Nanomedicine 1 2005 67 76 (Pubitemid 43963614)
227. K.S. Oh, J.A. Engler, and I. Joung Enhancement of gene delivery to cancer cells by a retargeted adenovirus J. Microbiol. 43 2005 179 182 (Pubitemid 40720621)
228. J.M. Rojek, and S. Kunz Cell entry by human pathogenic arenaviruses Cell. Microbiol. 10 2008 828 835 (Pubitemid 351386939)
229. S.F. Cotmore, and P. Tattersall Parvoviral host range and cell entry mechanisms Adv. Virus Res. 70 2007 183 232
230. P. Singh, G. Destito, A. Schneemann, and M. Manchester Canine parvovirus-like particles, a novel nanomaterial for tumor targeting J. Nanobiotechnol. 4 2006 2